CLPT250117C12500
- 3.97
- +0.57+16.76%
ClearPoint Neuro Newsroom
Lake Street Maintains ClearPoint Neuro(CLPT.US) With Buy Rating, Announces Target Price $17
Sector Update: Health Care Stocks Advance Pre-Bell Thursday
Sector Update: Health Care
Top Premarket Gainers
ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain
The ClearPoint Neuro, Inc. (NASDAQ:CLPT) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
Stifel Maintains ClearPoint Neuro(CLPT.US) With Buy Rating, Raises Target Price to $17
B.Riley Financial Maintains ClearPoint Neuro(CLPT.US) With Buy Rating, Raises Target Price to $15
B. Riley Adjusts Price Target on ClearPoint Neuro to $15 From $14, Maintains Buy Rating
Express News | Clearpoint Neuro Inc : Stifel Raises Target Price to $17 From $10
ClearPoint Neuro Inc (CLPT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...
ClearPoint Neuro, Inc. (CLPT) Q3 2024 Earnings Call Transcript Summary
Express News | Clearpoint Neuro Inc Files for Common Stock Offering of up to $50 Mln - SEC Filing
Express News | ClearPoint Neuro Affirms FY2024 Sales Guidance From $30.00M-33.00M to $30.00M-33.00M
ClearPoint Neuro GAAP EPS of -$0.18 Misses by $0.01, Revenue of $8.12M Beats by $0.34M
ClearPoint Neuro Achieves Strong Q3 Growth and Debt Repayment
ClearPoint Neuro | 10-Q: Q3 2024 Earnings Report
ClearPoint Neuro | 8-K: ClearPoint Neuro Reports Third Quarter 2024 Results
Earnings Flash (CLPT) CLEARPOINT NEURO Reports Q3 Revenue $8.1M
Express News | Clearpoint Neuro Q3 Gross Margin 60%